Press Releases

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Credit Suisse 18th Annual Health Care Conference on Wednesday, November...

-- Fiscal first quarter revenue from continuing operations increased $72 million, or 16%, to $528 million -- Fiscal first quarter GAAP income from continuing operations increased 59% to $61...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has signed a definitive agreement to sell its Israel Consumer Products business along with the related production assets in...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.0625 per share, payable on December 15, 2009 to shareholders of record on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its first quarter fiscal 2010 on Monday, November 2, 2009 at approximately 8:00 a.m. (ET). The...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that the Hatch-Waxman litigation relating to Duac® Gel (clindamycin phosphate (1%) and benzoyl peroxide (5%) gel) filed by the Stiefel...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has filed an Abbreviated New Drug Application for over-the-counter (OTC) Minoxidil topical aerosol foam, 5%, a generic form of...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) will hold its Investor Day from 8:30 a.m. to approximately 12:00 p.m. EDT on September 29, at the NASDAQ MarketSite located at 4 Times Square in New...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has purchased the ANDA for clindamycin phosphate (1%) and benzoyl peroxide (5%) gel from KV Pharmaceutical for $14 million in...